Can Peritoneal Cancer Be Cured? The Latest Outlook

Cure is possible for a subset of people with peritoneal cancer, but the honest answer depends on the type of cancer, how widely it has spread across the peritoneal lining, and whether a surgical team can remove all visible disease. For slow-growing tumors like low-grade pseudomyxoma peritonei, long-term disease-free survival after aggressive treatment is realistic. For more common scenarios like colorectal or gastric cancer that has spread to the peritoneum, “cure” is less certain, though meaningful survival gains have been documented in carefully selected patients. The treatment landscape has shifted considerably over the past decade, with heated chemotherapy baths, aerosolized drug delivery, and targeted molecular therapies all reshaping what is achievable.

The Central Treatment Strategy

The cornerstone of potentially curative treatment for peritoneal cancer is cytoreductive surgery, often abbreviated CRS. The goal is to physically strip and remove every bit of visible tumor from the peritoneal surfaces, including portions of the peritoneum itself and, when necessary, segments of nearby organs like the bowel, spleen, or gallbladder.¹ This is not a minor procedure. It can involve six to twelve hours in the operating room, and the extent depends on how many peritoneal regions carry tumor deposits.

In many centers, CRS is paired with hyperthermic intraperitoneal chemotherapy, or HIPEC. Once the surgeon has removed all visible disease, heated chemotherapy solution is circulated directly through the abdominal cavity for roughly 30 to 90 minutes. The heat itself is selectively toxic to cancer cells and also increases the penetration and potency of certain chemotherapy drugs.² This bath reaches tumor cells that the surgeon’s eye may have missed, particularly microscopic deposits lodged in peritoneal folds.

Why Tumor Spread Matters More Than Almost Anything Else

Surgeons quantify how much tumor covers the peritoneum using a scoring system called the peritoneal cancer index, or PCI, which divides the abdomen into thirteen regions and grades each on a scale from zero to three based on the largest tumor deposit found there. The total score ranges from zero to 39. This number has emerged as one of the strongest predictors of whether treatment will succeed.

In colorectal cancer that has spread to the peritoneum, a study with three years of follow-up found that PCI was the only independent predictor of death after CRS and HIPEC. Compared to patients with a PCI of 10 or below, those with scores between 11 and 20 had roughly three times the risk of dying, and patients with scores above 20 had more than seven times the risk.³ In that analysis, even achieving a complete visible resection did not independently predict survival once PCI was accounted for. A similar pattern holds in gastric cancer, where a multicenter Spanish study identified a PCI of 7 or above as the only factor independently worsening survival after CRS and HIPEC.⁴

Interestingly, the picture differs in ovarian cancer. A prospective study found that while a high PCI was associated with worse outcomes, the completeness of surgical removal was the stronger independent predictor of survival, with suboptimal cytoreduction roughly doubling the hazard of death.⁵ This matters practically: it means that in ovarian cancer, an aggressive surgical effort at achieving complete resection can partially overcome the disadvantage of high-volume disease.

How Outcomes Differ by Cancer Type

Peritoneal cancer is not one disease. The tumor that starts on or spreads to the peritoneum can originate from the appendix, ovaries, colon, stomach, or the peritoneum itself. The biology of the original cancer determines treatment response far more than the shared anatomic location.

Appendiceal Tumors and Pseudomyxoma Peritonei

The most favorable outcomes belong to low-grade appendiceal tumors, particularly pseudomyxoma peritonei (PMP), which fills the abdomen with mucinous material. A single-institution series spanning 22 years reported that patients who underwent CRS with HIPEC had a median survival of 92 months, with a five-year survival rate of about 62 percent and five-year recurrence-free survival of 61 percent.⁶ Low-grade PMP did better than high-grade: five-year survival was 64 percent for low-grade disease and 30 percent for high-grade tumors without signet ring cells. Some patients with low-grade PMP remain disease-free beyond ten years, which is as close to a functional cure as peritoneal oncology gets.

Ovarian and Primary Peritoneal Cancer

Ovarian cancer is one of the cancer types where adding HIPEC to surgery has shown the clearest benefit. A landmark Dutch trial randomized patients with advanced ovarian cancer undergoing interval surgery after initial chemotherapy. Those who received HIPEC had a median overall survival of nearly 46 months compared to about 34 months in the surgery-only group.⁷ Recurrence-free survival was also longer: about 14 months versus 11 months.

A subsequent randomized trial found an even wider gap, with median overall survival reaching nearly 62 months in the HIPEC group versus about 48 months without it for patients undergoing interval surgery after initial chemotherapy.⁸ A meta-analysis of randomized trials confirmed the pattern, finding that adding HIPEC to interval cytoreductive surgery significantly improved five-year survival.⁹ Primary peritoneal cancer, which arises from the peritoneal lining itself and behaves much like high-grade serous ovarian cancer, is treated with the same protocols.

Colorectal Cancer

Here the story gets more complicated. A large French randomized trial called PRODIGE 7 compared CRS plus HIPEC to CRS alone for colorectal peritoneal spread and found no survival difference. Median survival was about 42 months in both arms, and the HIPEC group actually had more late complications.¹⁰ This trial sent shock waves through the field, because it suggested that for colorectal cancer, the surgery itself was doing the heavy lifting.

That said, several researchers have pointed out limitations of the study, including the specific drug used (oxaliplatin at a short infusion time), the sample size, and the possibility that crossover and neoadjuvant chemotherapy in both groups may have muddied the results.¹¹ A recent consensus guideline involving over 140 experts emphasized that patients with colorectal peritoneal spread should still be referred early to a specialized center, but shifted toward recommending upfront systemic chemotherapy rather than rushing to the operating room.¹² The 42-month median survival with good CRS alone is still a meaningful result for what was once considered a uniformly fatal situation.

Gastric Cancer

Gastric cancer with peritoneal spread remains the toughest challenge. A multicenter Spanish study of 88 patients treated with CRS and HIPEC reported a median overall survival of about 21 months, with a three-year survival rate of roughly 31 percent.⁴ A more recent series of 104 patients found that about 18 percent survived three years or longer, and those who did tended to have lower PCI scores, moderately differentiated tumors, and positive peritoneal wash cytology only rather than visible tumor deposits.¹³ There is no international consensus on optimal treatment here, and patient selection is debated actively.¹⁴

Newer Ways of Delivering Drugs to the Peritoneum

One of the most watched developments in this field is pressurized intraperitoneal aerosol chemotherapy, or PIPAC, which uses a special device to spray chemotherapy as a fine mist under pressure during a laparoscopic procedure. Because the drugs are aerosolized, they penetrate peritoneal tumor deposits more uniformly than liquid instillation. A systematic review of PIPAC in ovarian cancer found it to be safe and effective for palliative use, with good tumor response and quality of life, though the authors noted that studies exploring curative use are still needed.¹⁵

In gastric cancer, a meta-analysis found that patients who received three or more PIPAC sessions showed significantly better survival, gaining roughly six additional months compared to those with fewer sessions, along with higher rates of tumor response on biopsy and without longer hospital stays.¹⁶ PIPAC is increasingly being explored as a bridge treatment, shrinking peritoneal disease before patients undergo a full CRS, potentially converting previously inoperable cases into operable ones.

Targeted and Immune-Based Therapies

For ovarian and primary peritoneal cancers, PARP inhibitors have become a standard part of treatment. These drugs block a DNA repair pathway that certain tumors depend on, and they are now recommended as maintenance therapy after initial chemotherapy response to delay relapse.¹⁷ Patients with BRCA mutations or other DNA repair deficiencies benefit most, and these drugs have extended remission periods meaningfully for many patients.

Immunotherapy has been slower to gain traction in peritoneal cancer. The peritoneal cavity can be an immunologically “cold” environment, and research suggests that the immune marker PD-L1 is often expressed at lower levels on peritoneal tumors than at other sites. Still, there are encouraging signals. In gastric cancer, the ATTRACTION-2 trial showed that the checkpoint inhibitor nivolumab had activity even in heavily pretreated patients, about 30 percent of whom had peritoneal involvement.¹⁸ Researchers are also investigating more inventive approaches, including delivering engineered immune cells and checkpoint inhibitors directly into the peritoneal cavity, and early work with CAR-T cells directed against peritoneal tumors has shown promise in laboratory and early clinical settings.¹⁹

Tracking the Disease With Liquid Biopsy

One of the persistent challenges in peritoneal cancer is monitoring whether treatment is working and catching recurrence early. Standard blood-based liquid biopsies, which detect fragments of tumor DNA circulating in the bloodstream, have a particular weakness here: peritoneal tumors shed less DNA into the blood than tumors at other sites, making them harder to detect this way.²⁰

A promising workaround is analyzing peritoneal fluid directly. Tumor DNA collected from peritoneal washes has been found at much higher concentrations than in blood. In one study, patients whose peritoneal fluid tested negative for tumor DNA after CRS and HIPEC did not develop peritoneal recurrence, while those with detectable tumor DNA in peritoneal fluid after treatment went on to relapse.²¹ Combining blood and peritoneal fluid analysis could eventually give clinicians a real-time window into whether microscopic disease persists after treatment.

What Recovery Looks Like

CRS with or without HIPEC is one of the most demanding operations in surgical oncology, and patients should know what they are signing up for. In one prospective study, about a third of patients experienced major complications, including abdominal abscesses, bleeding, fluid collections around the lungs, and bowel leaks. Patients with major complications spent a median of about 36 days in the hospital, compared to about 13 days for those without.²² However, and this is reassuring, quality of life at six months did not differ significantly between patients who had complications and those who did not. The most bothersome lingering symptoms were diarrhea and fatigue. This suggests that while the early recovery period can be brutal, most patients adapt and return to a reasonable baseline within months.

Preoperative Imaging and Patient Selection

Choosing who benefits from CRS is arguably as important as the surgery itself. Dedicated peritoneal MRI, using sequences optimized to pick up small tumor deposits that CT scanning routinely misses, has become increasingly important at specialized centers. A standardized MRI protocol can map tumor locations across all peritoneal regions, giving surgeons a much better sense of whether complete resection is feasible before opening the abdomen.²³ This reduces the number of futile surgeries where the abdomen is opened only to find disease that cannot be fully cleared.

Getting Access to Specialized Treatment

One of the most underappreciated barriers to cure is simply geography. CRS and HIPEC are performed at specialized centers, and most patients must travel significant distances. In a U.S. study, more than half of patients traveled over 100 miles for treatment.²⁴ A separate Medicare-based analysis found that only a tiny fraction of eligible patients with colorectal or appendiceal peritoneal spread actually underwent CRS/HIPEC, or even had an outpatient visit with a surgeon who specializes in peritoneal disease. Patients with higher social vulnerability and those living farther from specialized centers were significantly less likely to receive treatment.²⁵

The disparities go deeper than geography. An analysis of national data found that patients undergoing HIPEC were disproportionately white, English-speaking, and privately insured, with higher average incomes than patients receiving less specialized colorectal surgery.²⁶ These access gaps are troubling because they mean that a potentially curable situation may go untreated simply because the right referral was never made or the patient could not afford the trip. For anyone diagnosed with peritoneal cancer, seeking a consultation at a peritoneal surface malignancy center, even a remote one, is worth the effort. Consensus guidelines now emphasize early referral to these centers regardless of whether CRS is ultimately performed.

Nanoparticle Drug Delivery on the Horizon

One of the limitations of current intraperitoneal chemotherapy is that drugs are cleared from the abdominal cavity relatively quickly, reducing the time they spend in contact with tumor cells. Researchers are working on nanoparticle-based delivery systems designed to keep drugs in the peritoneal space longer and target them more precisely to cancer cells.²⁷ In animal studies, bioadhesive nanoparticles that stick to the lining of the abdominal cavity have shown significantly extended drug retention and higher effectiveness against chemotherapy-resistant peritoneal tumors, with lower systemic side effects than free drug.²⁸ These technologies are still preclinical, but they represent a potential step change: if you could keep a high concentration of drug exactly where it is needed for days instead of hours, the effectiveness of intraperitoneal treatment could improve substantially without increasing the toxicity patients feel elsewhere in the body.²⁹